Hemochromatosis Type 1SAIFERNCT01810965
Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis
A study of Hemochromatosis Type 1, run by Rennes University Hospital at 1 site in France.
Trial summary
Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about 3/1000 white subjects (5/1000 in Brittany, France). Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Hemochromatosis Type 1
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 1 siteFrance
- Study dates
- 3 Jun 2013to 19 Apr 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men
- Age 18 years or older
- Homozygosity for the C282Y mutation of the HFE gene
- With an indication of treatment by bloodletting (in accordance with the French HAS guidelines)
- Ferritinemia ≥ 500µg/L
- Transferrin saturation ≥ 75%
- Never treated by bloodletting
- Written informed consent
Who cannot join
- Contraindication to bloodletting
- Chronic inflammatory or dysmetabolic or neoplastic disease
- Major cardiovascular disease
- Excessive consumption of alcohol (≥ 3gr/day)
- Treatment by iron chelators, C or E vitamins
- Stay in altitude> 1500m in the month preceding the period Day 1
Show all 9Show fewer
- Patients under guardianship
- Blood donation in the 3 past months
- Night / shift workers
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis: Pathophysiological and Clinical Implications. Pilot Study.
Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about 3/1000 white subjects (5/1000 in Brittany, France).
For the half of these predisposed subjects, the phenotypic expression of the disease needs a treatment. This treatment is based upon repeated bloodletting which is generally considered as simple, safe and effective.
Nevertheless, it is still questioned as regard its physiopathological justification and its clinical implications. Indeed, bloodletting could cause an increase of non-transferrin bound iron (NTBI) particularly for its reactive form called labile plasma iron (LPI) This adverse physiopathological effect could have clinical consequences and could be linked with articular consequences which can be aggravated by the treatment.
Read the detailed description
Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about 3/1000 white subjects (5/1000 in Brittany, France).
For the half of these predisposed subjects, the phenotypic expression of the disease needs a treatment. This treatment is based upon repeated bloodletting which is generally considered as simple, safe and effective.
Nevertheless, it is still questioned as regard its physiopathological justification and its clinical implications. Indeed, bloodletting could cause an increase of non-transferrin bound iron (NTBI) particularly for its reactive form called labile plasma iron (LPI) This adverse physiopathological effect could have clinical consequences and could be linked with articular consequences which can be aggravated by the treatment.
The primary objective is to explore the effect of bloodletting upon plasmatic concentrations of NTBI.
The secondary objectives are to:
- explore the impact of bloodletting upon different parameters of iron metabolism and in particular LPI, hepcidinemia and markers of erythropoiesis ;
- explore basal and nycthemeral characteristics of new parameters of iron metabolism (hepcidin, NTBI, LPI) in hemochromatosis patients.
The demonstration of an adverse effect of bloodletting upon iron metabolism would allow for a therapeutic innovation based upon an association of bloodletting and oral chelation during the induction treatment of type 1 hemochromatosis and, more generally in hepcidino deficient forms of hemochromatosis.
- Conditions
- Hemochromatosis Type 1
- Being tested
- First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)
- Keywords
- Hemochromatosis type 1
- Medical subject headings
- Hemochromatosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)Procedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| Cohort | Experimental | Not described Receives: Procedure: First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximal variation (delta maximum) of NTBI during the 5 days following a bloodletting
Measured: Day 5
Secondary outcomes (14)
Kinetic of NTBI plasmatic concentration during the 5 days following a bloodletting
Measured: Day 5
Maximal variation (delta maximum) of LPI during the 5 days following a bloodletting
Measured: Day 5
Maximal variation (delta maximum) of hepcidin during the 5 days following a bloodletting
Measured: Day 5
Kinetic of LPI plasmatic concentration during the 5 days following a bloodletting
Measured: Day 5
Kinetic of hepcidin plasmatic concentration during the 5 days following a bloodletting
Measured: Day 5
CRP
Measured: Day 9, day 10, day 11 and day 12
Hemoglobin
Measured: Day 9, day 10, day 11 and day 12
Soluble transferrin receptor
Measured: Day 9, day 10, day 11 and day 12
EPO
Measured: Day 9, day 10, day 11 and day 12
Circadian kinetic of NTBI plasmatic concentration when no bloodletting is performed
Measured: Day 1
Circadian kinetic of API plasmatic concentration when no bloodletting is performed
Measured: Day 1
Circadian kinetic of hepcidine plasmatic concentration when no bloodletting is performed
Measured: Day 1
Maximal variation (delta maximum) of transferrin saturation during the 5 days following a bloodletting
Measured: Day 5
Kinetic of transferrin saturation during the 5 days following a bloodletting
Measured: Day 5
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2013 (estimated)
- Study start3 Jun 2013
- Primary completion19 Apr 2019
- Study completion19 Apr 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hemochromatosis Type 1Studies of the same condition, open and under way.
- More trials run by Rennes University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rennes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Martine Ropert-Bouchet, MD, Principal investigator, Rennes University HospitalBruno Laviolle, MD, PhD, Study chair, Rennes University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01810965
- Sponsor's protocol ID
- ANSM 2012-A01392-41
- Acronym
- SAIFER
- Status last verified
- Jun 2021
- First submitted
- 12 Mar 2013
- Last updated
- 11 Jun 2021
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis: Pathophysiological and Clinical Implications. Pilot Study.
- ClinicalTrials.gov ID
- NCT01810965
- Acronym / sponsor ID
- SAIFER / ANSM 2012-A01392-41
- Conditions
- Hemochromatosis Type 1
- Keywords
- Hemochromatosis type 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 6 participants (actual)
- Lead sponsor
- Rennes University HospitalUniversity, hospital or other
- Study start
- 3 Jun 2013 (actual)
- Primary completion
- 19 Apr 2019 (actual)
- Study completion
- 19 Apr 2019 (actual)
- First posted
- 14 Mar 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about 3/1000 white subjects (5/1000 in Brittany, France).
For the half of these predisposed subjects, the phenotypic expression of the disease needs a treatment. This treatment is based upon repeated bloodletting which is generally considered as simple, safe and effective.
Nevertheless, it is still questioned as regard its physiopathological justification and its clinical implications. Indeed, bloodletting could cause an increase of non-transferrin bound iron (NTBI) particularly for its reactive form called labile plasma iron (LPI) This adverse physiopathological effect could have clinical consequences and could be linked with articular consequences which can be aggravated by the treatment.
Detailed description
Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about 3/1000 white subjects (5/1000 in Brittany, France).
For the half of these predisposed subjects, the phenotypic expression of the disease needs a treatment. This treatment is based upon repeated bloodletting which is generally considered as simple, safe and effective.
Nevertheless, it is still questioned as regard its physiopathological justification and its clinical implications. Indeed, bloodletting could cause an increase of non-transferrin bound iron (NTBI) particularly for its reactive form called labile plasma iron (LPI) This adverse physiopathological effect could have clinical consequences and could be linked with articular consequences which can be aggravated by the treatment.
The primary objective is to explore the effect of bloodletting upon plasmatic concentrations of NTBI.
The secondary objectives are to:
- explore the impact of bloodletting upon different parameters of iron metabolism and in particular LPI, hepcidinemia and markers of erythropoiesis ;
- explore basal and nycthemeral characteristics of new parameters of iron metabolism (hepcidin, NTBI, LPI) in hemochromatosis patients.
The demonstration of an adverse effect of bloodletting upon iron metabolism would allow for a therapeutic innovation based upon an association of bloodletting and oral chelation during the induction treatment of type 1 hemochromatosis and, more generally in hepcidino deficient forms of hemochromatosis.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cohort | Experimental | Procedure: First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml) |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Men
- Age 18 years or older
- Homozygosity for the C282Y mutation of the HFE gene
- With an indication of treatment by bloodletting (in accordance with the French HAS guidelines)
- Ferritinemia ≥ 500µg/L
Key exclusion criteria (9 listed)
- Contraindication to bloodletting
- Chronic inflammatory or dysmetabolic or neoplastic disease
- Major cardiovascular disease
- Excessive consumption of alcohol (≥ 3gr/day)
- Treatment by iron chelators, C or E vitamins
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml) | Procedure or surgery | Cohort |
Primary outcome
Maximal variation (delta maximum) of NTBI during the 5 days following a bloodletting
Time frame: Day 5
14 secondary outcomes
Kinetic of NTBI plasmatic concentration during the 5 days following a bloodletting
Time frame: Day 5
Maximal variation (delta maximum) of LPI during the 5 days following a bloodletting
Time frame: Day 5
Maximal variation (delta maximum) of hepcidin during the 5 days following a bloodletting
Time frame: Day 5
Kinetic of LPI plasmatic concentration during the 5 days following a bloodletting
Time frame: Day 5
Kinetic of hepcidin plasmatic concentration during the 5 days following a bloodletting
Time frame: Day 5
CRP
Time frame: Day 9, day 10, day 11 and day 12
Hemoglobin
Time frame: Day 9, day 10, day 11 and day 12
Soluble transferrin receptor
Time frame: Day 9, day 10, day 11 and day 12
EPO
Time frame: Day 9, day 10, day 11 and day 12
Circadian kinetic of NTBI plasmatic concentration when no bloodletting is performed
Time frame: Day 1
Circadian kinetic of API plasmatic concentration when no bloodletting is performed
Time frame: Day 1
Circadian kinetic of hepcidine plasmatic concentration when no bloodletting is performed
Time frame: Day 1
Maximal variation (delta maximum) of transferrin saturation during the 5 days following a bloodletting
Time frame: Day 5
Kinetic of transferrin saturation during the 5 days following a bloodletting
Time frame: Day 5
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2021.
Related trials for Hemochromatosis Type 1
Active, not recruitingPhase 2
Treatment of Hemochromatosis
Hemochromatosis
Active, not recruitingPhase 2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Active, not recruiting
Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis
Haemochromatosis
RecruitingPhase 1/2
A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis
Hereditary Hemochromatosis
RecruitingObservational study
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Chronic Liver Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Martine Ropert-Bouchet, MD principal investigator
Rennes University Hospital
Bruno Laviolle, MD, PhD study chair
Rennes University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Hemochromatosis Type 1, run by Rennes University Hospital at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximal variation (delta maximum) of NTBI during the 5 days following a bloodletting (time frame: Day 5). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2021.